Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein

Abstract

To gain more insight into the pharmacological role of endogenous P-glycoprotein in the metabolism of the widely used substrate drug doxorubicin, we have studied the plasma pharmacokinetics, tissue distribution and excretion of this compound in mdr1a(-/-) and wild-type mice. Doxorubicin was administered as an i.v. bolus injection at a dose level of 5 mg kg(-1). Drug and metabolite concentrations were determined in plasma, tissues, urine and faeces by high-performance liquid chromatography. In comparison with wild-type mice, the terminal half-life and the area under the plasma concentration-time curve of doxorubicin in mdr1a(-/-) mice were 1.6- and 1.2-fold higher respectively. The retention of both doxorubicin and its metabolite doxorubicinol in the hearts of mdr1a(-/-) mice was substantially prolonged. In addition, a significantly increased drug accumulation was observed in the brain and the liver of mdr1a(-/-) mice. The relative accumulation in most other tissues was not or only slightly increased. The differences in cumulative faecal and urinary excretion of doxorubicin and metabolites between both types of mice were small. These experiments demonstrate that the absence of mdr1a P-glycoprotein only slightly alters the plasma pharmacokinetics of doxorubicin. Furthermore, the substantially prolonged presence of both doxorubicin and doxorubicinol in cardiac tissue of mdr1a(-/-) mice suggests that a blockade of endogenous P-glycoprotein in patients, for example by a reversal agent, may enhance the risk of cardiotoxicity upon administration of doxorubicin.

References 27

1. 1.

   Bartlett N. L., Lum B. L., Fisher G. A., Brophy N. A., Ehsan M. N., Halsey J., Sikic B. I. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol. 1994;12(4):835-842.

   Not in our library10.1200/jco.1994.12.4.835

2. 2.

   Bellamy W. T., Peng Y. M., Odeleye A., Ellsworth L., Xu M. J., Grogan T. M., Weinstein R. S. Cardiotoxicity in the SCID mouse following administration of doxorubicin and cyclosporin A. Anticancer Drugs. 1995;6(6):736-743.

   Not in our library10.1097/00001813-199512000-00004

3. 3.

   Colombo T., Zucchetti M., D'Incalci M. Cyclosporin A markedly changes the distribution of doxorubicin in mice and rats. J Pharmacol Exp Ther. 1994;269(1):22-27.

   Not in our library

4. 4.

   Cordon-Cardo C., O'Brien J. P., Casals D., Rittman-Grauer L., Biedler J. L., Melamed M. R., Bertino J. R. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A. 1989;86(2):695-698.

   Not in our library10.1073/pnas.86.2.695

5. 5.

   Croop J. M., Raymond M., Haber D., Devault A., Arceci R. J., Gros P., Housman D. E. The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol Cell Biol. 1989;9(3):1346-1350.

   Not in our library10.1128/mcb.9.3.1346-1350.1989

6. 6.

   Dantzig A. H., Shepard R. L., Cao J., Law K. L., Ehlhardt W. J., Baughman T. M., Bumol T. F., Starling J. J. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res. 1996;56(18):4171-4179.

   Not in our library

7. 7.

   Endicott J. A., Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem. 1989;58:137-171.

   Not in our library10.1146/annurev.bi.58.070189.001033

8. 8.

   Erlichman C., Moore M., Thiessen J. J., Kerr I. G., Walker S., Goodman P., Bjarnason G., DeAngelis C., Bunting P. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. Cancer Res. 1993;53(20):4837-4842.

   Not in our library

9. 9.

   Giaccone G., Linn S. C., Welink J., Catimel G., Stieltjes H., van der Vijgh W. J., Eeltink C., Vermorken J. B., Pinedo H. M. A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors. Clin Cancer Res. 1997;3(11):2005-2015.

   Not in our library

10. 10.

    Gonzalez O., Colombo T., De Fusco M., Imperatori L., Zucchetti M., D'Incalci M. Changes in doxorubicin distribution and toxicity in mice pretreated with the cyclosporin analogue SDZ PSC 833. Cancer Chemother Pharmacol. 1995;36(4):335-340.

    Not in our library10.1007/bf00689051

11. 11.

    Hyafil F., Vergely C., Du Vignaud P., Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res. 1993;53(19):4595-4602.

    Not in our library

12. 12.

    Mayer U., Wagenaar E., Beijnen J. H., Smit J. W., Meijer D. K., van Asperen J., Borst P., Schinkel A. H. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein. Br J Pharmacol. 1996;119(5):1038-1044.

    Not in our library10.1111/j.1476-5381.1996.tb15775.x

13. 13.

    Mayer U., Wagenaar E., Dorobek B., Beijnen J. H., Borst P., Schinkel A. H. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J Clin Invest. 1997;100(10):2430-2436.

    Not in our library10.1172/jci119784

14. 14.

    Mross K., Maessen P., van der Vijgh W. J., Gall H., Boven E., Pinedo H. M. Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans. J Clin Oncol. 1988;6(3):517-526.

    Not in our library10.1200/jco.1988.6.3.517

15. 15.

    Olson R. D., Mushlin P. S., Brenner D. E., Fleischer S., Cusack B. J., Chang B. K., Boucek R. J. Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proc Natl Acad Sci U S A. 1988;85(10):3585-3589.

    Not in our library10.1073/pnas.85.10.3585

16. 16.

    Schinkel A. H., Mayer U., Wagenaar E., Mol C. A., van Deemter L., Smit J. J., van der Valk M. A., Voordouw A. C., Spits H., van Tellingen O. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci U S A. 1997;94(8):4028-4033.

    Not in our library10.1073/pnas.94.8.4028

17. 17.

    Schinkel A. H., Smit J. J., van Tellingen O., Beijnen J. H., Wagenaar E., van Deemter L., Mol C. A., van der Valk M. A., Robanus-Maandag E. C., te Riele H. P. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 1994;77(4):491-502.

    Not in our library10.1016/0092-8674(94)90212-7

18. 18.

    Schinkel A. H., Wagenaar E., Mol C. A., van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest. 1996;97(11):2517-2524.

    Not in our library10.1172/jci118699

19. 19.

    Schinkel A. H., Wagenaar E., van Deemter L., Mol C. A., Borst P. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest. 1995;96(4):1698-1705.

    Not in our library10.1172/jci118214

20. 20.

    Sparreboom A., van Asperen J., Mayer U., Schinkel A. H., Smit J. W., Meijer D. K., Borst P., Nooijen W. J., Beijnen J. H., van Tellingen O. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci U S A. 1997;94(5):2031-2035.

    Not in our library10.1073/pnas.94.5.2031

21. 21.

    Thiebaut F., Tsuruo T., Hamada H., Gottesman M. M., Pastan I., Willingham M. C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A. 1987;84(21):7735-7738.

    Not in our library10.1073/pnas.84.21.7735

22. 22.

    Tsuruo T., Iida H., Tsukagoshi S., Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 1981;41(5):1967-1972.

    Not in our library

23. 23.

    Wacher V. J., Wu C. Y., Benet L. Z. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog. 1995;13(3):129-134.

    Not in our library10.1002/mc.2940130302

24. 24.

    Webster L. K., Cosson E. J., Stokes K. H., Millward M. J. Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice. Br J Cancer. 1996;73(4):522-524.

    Not in our library10.1038/bjc.1996.90

25. 25.

    de Jong J., Schoofs P. R., Snabilié A. M., Bast A., van der Vijgh W. J. The role of biotransformation in anthracycline-induced cardiotoxicity in mice. J Pharmacol Exp Ther. 1993;266(3):1312-1320.

    Not in our library

26. 26.

    van Asperen J., Schinkel A. H., Beijnen J. H., Nooijen W. J., Borst P., van Tellingen O. Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice. J Natl Cancer Inst. 1996;88(14):994-999.

    Not in our library10.1093/jnci/88.14.994

27. 27.

    van Asperen J., van Tellingen O., Beijnen J. H. Determination of doxorubicin and metabolites in murine specimens by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 1998;712(1-2):129-143.

    Not in our library10.1016/s0378-4347(98)00165-0

Cited by papers we hold 3

• Identification of new candidate biomarkers to support doxorubicin treatments in canine cancer patients · 2021
  Not checked
• A comprehensive review in improving delivery of small-molecule chemotherapeutic agents overcoming the blood-brain/brain tumor barriers for glioblastoma treatment · 2019
  No notice
• Doxorubicin-induced cardiomyopathy associated with inhibition of autophagic degradation process and defects in mitochondrial respiration · 2019
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.